Ratings by Citi (Laura Sutcliffe)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 7/13/2026 | ResMed | RMD | Downgrade | Neutral (Buy) |
208.45 (198.99) |
-4.54% | Details | |
| 7/7/2026 | Telix Pharmaceuticals Ltd | TLX | Maintain | Buy (N/A) |
|
Details | ||
| 9/18/2025 | ResMed | RMD | New Coverage | Buy (N/A) |
271.71 (198.99) |
-26.76% | Details | |
| 9/18/2025 | Telix Pharmaceuticals Ltd | TLX | New Coverage | Buy (N/A) |
9.38 (10.46) |
11.51% | Details |
